vigabatrin
RxCUI 14851
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Vigabatrin
Vigabatrin, sold under the brand name Vigafyde among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors. Vigabatrin is generally used only in cases of treatment-resistant epilepsy due to the risk of permanent vision loss. Although estimates of visual field loss vary substantially, risk appears to be lower among infants with treatment duration less than 12 months and the risk of clinically meaningful vision loss is very low among children treated for infantile spasms.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
3 shownConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.